Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Vanda Pharmaceuticals
Deal Size : $45.0 million
Deal Type : Licensing Agreement
Vanda, Anaptys Sign Global License for IL-36R Antagonist Imsidolimab
Details : Under the licensing agreement, Vanda will hold the exclusive rights for the development & commercialization of ANB019 (imsidolimab). It is being evaluated for treating Generalized Pustular Psoriasis.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : $10.0 million
February 03, 2025
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Vanda Pharmaceuticals
Deal Size : $45.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ANB032
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anaptys Announces Phase 2b Trial of ANB032 Did Not Meet Endpoints in Atopic Dermatitis
Details : ANB032 is a BTLA agonist antibody candidate, which is being evaluated for the treatment of patients with atopic dermatitis eczema.
Product Name : ANB032
Product Type : Antibody
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : ANB032
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anaptys Reports Positive Results from GEMINI-2 Phase 3 Trial of Imsidolimab in Psoriasis
Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
September 05, 2024
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANB032
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : TD Cowen
Deal Size : $100.0 million
Deal Type : Public Offering
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Details : The net proceeds will be used to fund the clinical development of the company's lead product ANB032 BTLA agonist antibody, which is being evaluated for the treatment of Atopic Dermatitis Eczema.
Product Name : ANB032
Product Type : Antibody
Upfront Cash : Undisclosed
August 14, 2024
Lead Product(s) : ANB032
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : TD Cowen
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
September 10, 2023
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rosnilimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
Details : ANB030 (Rosnilimab), its investigational wholly owned PD-1 agonist, demonstrates best-in-class activity in vitro with superior inhibition of T cell proliferation, reduction in inflammatory cytokine secretion (Th1, Th2, Th17) and depletion of PD-1+ T cell...
Product Name : ANB030
Product Type : Antibody
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : Rosnilimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ANB019 (Imsidolimab) previously demonstrated efficacy and safety in the GALLOP Phase 2 trial in generalized pustular psoriasis (GPP), a systemic, life-threatening inflammatory disease in which imsidolimab has been granted Orphan Disease Designation.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
Details : Imsidolimab demonstrated efficacy and safety in GALLOP Phase 2 trial in generalized pustular psoriasis (GPP) and enrollment of the GEMINI-1 GPP Phase 3 trial is ongoing and top-line data from the imsidolimab HARP Phase 2 trial is anticipated during secon...
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
August 03, 2021
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) therapeutic antibody used for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, acne and hidradenitis suppurativa.
Product Name : ANB019
Product Type : Antibody
Upfront Cash : Inapplicable
February 10, 2021
Lead Product(s) : Imsidolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable